Canadian rope trick

7 December 2018 By John Foley Follow @johnsfoley

Marlboro maker Altria is spending $1.8 billion – more than a 40 percent premium – for a 45 percent stake in pot grower Cronos. The valuation is both high and irrelevant. Cannabis is beginning to adopt Silicon Valley’s belief that the winner is whoever has the most cash.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.

Context News

Altria agreed to spend $1.8 billion, or C$16.25 per share, on a 45 percent stake in Canadian cannabis producer Cronos, it said on Dec. 7.

The U.S. tobacco group will buy shares at a 41.5 percent premium to their 10-day average price before Nov. 30, when Cronos said the two were in talks.

Altria would also get a warrant to take its stake up to 55 percent at a price of C$19 per share, roughly a two-thirds premium to the same 10-day average price.

Constellation Brands said on Aug. 15 that it would invest $4 billion for shares and warrants in Canopy Growth, another Canadian cannabis company.

That earlier deal was struck at a 37.9 percent premium to Canopy’s five-day average share price at the time.

Email a friend

Please complete the form below.

Required fields *